The National Cancer Institute (NCI) awarded a $2,561,215 Project Grant (CFDA 93.396 Cancer Biology Research) to Weill Medical College of Cornell University to conduct a study titled "Epigenetic Basis and Therapeutic Targeting of the Unique Lymphoma Immunological Niche." The 5-year research project, which began on August 12, 2024, aims to gain a better understanding of the biological heterogeneity of diffuse large B-cell lymphoma (DLBCL) and how key genetic mutations and the tumor microenvironment interact to influence disease pathogenesis and potential therapeutic strategies. The research team, which includes experts across various fields, will leverage advanced technologies and model systems to investigate the central hypotheses around the role of chromatin regulation, immune synapse signaling, and age-related factors in shaping the DLBCL tumor microenvironment. The findings from this comprehensive, multidisciplinary research effort are expected to provide critical insights that can inform the development of more effective and precise treatment approaches for this aggressive form of lymphoma.
Generated 1/28/25, 9:32 AM